Stay updated on PD-1 Inhibition & Ablation for Advanced HCC Clinical Trial

Sign up to get notified when there's something new on the PD-1 Inhibition & Ablation for Advanced HCC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the PD-1 Inhibition & Ablation for Advanced HCC Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    Change Detected
    Summary
    The study has been updated to version v2.10.0, replacing the previous version v2.9.7.
    Difference
    0.5%
    Check dated 2024-07-23T14:39:44.000Z thumbnail image
  5. Check
    5 days ago
    No Change Detected
  6. Check
    11 days ago
    Change Detected
    Summary
    The website has been updated to Revision v2.9.7 from v2.9.6.
    Difference
    0.1%
    Check dated 2024-07-16T07:17:10.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.9.5 to v2.9.6, indicating a recent change in the webpage content.
    Difference
    0.1%
    Check dated 2024-07-02T14:05:44.000Z thumbnail image
  8. Check
    30 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.9.3 to v2.9.5, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-27T09:48:44.000Z thumbnail image
  9. Check
    31 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.9.1 to v2.9.3, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-26T08:37:07.000Z thumbnail image
  10. Check
    32 days ago
    Change Detected
    Summary
    The value 'Show more Show more Revision: v2.9.0' has been updated to 'Show less Drug Information available for: Nivolumab Pembrolizumab FDA Drug and Device Resources Show less Design Details Primary Purpose : Treatment Allocation : N/A Interventional Model : Single Group Assignment Interventional Model Description: The study subjects were those who with advanced HCC that progressed on first-line sorafenib and treated with anti-PD-1 therapy in combination with incomplete thermal ablation. Masking : None (Open Label) Arms and Interventions Participant Group/Arm Intervention/Treatment Experimental : Study arm Patients with stable diseases or atypical progression to ICIs monotherapy would be additionally treated with incomplete thermal ablation along with ICIs therapy; and for those who with no lesions eligible for Incomplete ablation, ICIs would be given solely. Others with complete or partial responses would keep on going with mono-ICIs therapy. Drug : pembrolizumab or nivolumab or JS001 ICIs therapy of nivolumab (3 mg/kg, per 2 weeks) or pembrolizumab (2 mg/kg, per 3 weeks) or JS001 (240mg, per 3 weeks) was performed until the off-treatment criteria were met. For participants with stable disease or atypical progression to ICIs therapy, thermal ablation of radiofrequency ablation or microwave ablation was performed addtionally. Other Names: computed tomography guided radiofrequency ablation or computed tomography guided microwave ablation Primary Outcome Measures Outcome Measure Measure Description Time Frame Adverse events Safety evaluation was done continuously during ICIs treatment and up to 30 days after the last dose by using the Common Terminology Criteria for Adverse Events (CTCAE; version 4.03). Complications related to ablation procedure were assessed peri-operation period and reported according to the standardized Society of Interventional Radiology grading system. 6-8 weeks Response Efficacy included objective response (includes complete and partial response), duration of response, and disease control (Includes complete and partial response, stable disease and atypical progression for at least 3 months). 6-8 weeks Secondary Outcome Measures Outcome Measure Measure Description Time Frame Time to tumor progression time from first dose of ICIs drug until the first typical progression of disease 3-4 months Progression-free survival time from first day of ICIs treatment to first typical disease progression, or death, which occurred earlier 3-4 months Overall survival time from first study treatment to death of any cause 3-4 months Keywords Provided by Ming Zhao, Sun Yat-sen University Hepatocellular carcinoma Immunotherapy Nivolumab Pembrolizumab Radiofrequency Ablation Microwave ablation Additional Relevant MeSH Terms Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Adenocarcinoma Liver Neoplasms Digestive System Neoplasms Neoplasms by Site Digestive System Diseases Liver Diseases Carcinoma Carcinoma, Hepatocellular Antineoplastic Agents, Immunological Antineoplastic Agents Immune Checkpoint Inhibitors Molecular Mechanisms of Pharmacological Action Pembrolizumab Nivolumab Plan to Share Individual Participant Data (IPD)? No Studies a U.S. FDA-Regulated Drug Product No Studies a U.S. FDA-Regulated Device Product No Product Manufactured in and Exported from the U.S. No Revision: v2.9.1'
    Difference
    31%
    Check dated 2024-06-25T08:17:39.000Z thumbnail image

Stay in the know with updates to PD-1 Inhibition & Ablation for Advanced HCC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the PD-1 Inhibition & Ablation for Advanced HCC Clinical Trial page.